SEC Comment Letter 0000000000-26-001607 to ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC
Date: Feb. 17, 2026 · CIK: 0001177648 · Accession: 0000000000-26-001607
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-293390
Letter
Re: Enanta Pharmaceuticals Inc. Registration Statement on Form S-3 Filed February 11, 2026 File No. 333-293390 Dear Jay R. Luly, Ph.D.:
February 17, 2026
Jay R. Luly, Ph.D. Chief Executive Officer Enanta Pharmaceuticals Inc. 4 Kingsbury Avenue Watertown, Massachusetts 02472
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Stacie Aarestad
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> February 17, 2026 Jay R. Luly, Ph.D. Chief Executive Officer Enanta Pharmaceuticals Inc. 4 Kingsbury Avenue Watertown, Massachusetts 02472 Re: Enanta Pharmaceuticals Inc. Registration Statement on Form S-3 Filed February 11, 2026 File No. 333-293390 Dear Jay R. Luly, Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stacie Aarestad </TEXT> </DOCUMENT>